Learn about the milestones we reached together with our partners in 2018, the revenues we generated and interesting emerging trends. The key points at a glance:
- 3 further research institutes gained as long-term partners, making a total of 28 public research institutes in Europe supported by us
- 119 invention disclosures assessed for these partners and 45 patent applications managed
- over 15 translation and start-up projects accompanied intensively
- 2 successful exits, including the sale of Vakzine Projekt Management GmbH (VPM) to the Serum Institute of India Pvt. Ltd (SII)
- 58 revenue-generating materials sales, licences and options closed with industry partners
- over 140 further agreements relating to commercial exploitation supported
- 3 drug candidates in clinical development
- 2 previously approved therapies granted extended approval
The revenues totalling EUR 5.4 million earned by our partners from licence agreements supported by us were lower than in the previous year, whereas the revenues from equity transactions of around EUR 4.7 million greatly exceed those achieved in 2017. This reflects a central trend: start-ups are not only gaining importance as vehicles for the translation of new technologies, products and services into application, but also as a source of revenue for the academic institutions at which the underlying research results and IP rights originated.
Further details and selected projects are described in our Annual Review. We wish you a stimulating read!
